UBS Group Has Lowered Expectations for Elanco Animal Health (NYSE:ELAN) Stock Price

Elanco Animal Health (NYSE:ELAN) had its target price dropped by investment analysts at UBS Group from $18.00 to $17.00 in a note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. UBS Group’s target price would indicate a potential upside of 55.61% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. Barclays cut their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a research report on Wednesday. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research report on Friday, February 21st. Morgan Stanley dropped their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Wednesday. Finally, Leerink Partners initiated coverage on Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 target price for the company. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat.com, Elanco Animal Health currently has a consensus rating of “Hold” and a consensus target price of $15.83.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $10.93 on Wednesday. The firm has a market cap of $5.40 billion, a P/E ratio of 27.31, a P/E/G ratio of 2.50 and a beta of 1.42. Elanco Animal Health has a 52-week low of $10.20 and a 52-week high of $18.80. The business’s 50-day moving average price is $11.72 and its 200 day moving average price is $13.05. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The company’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.08 earnings per share. On average, equities research analysts expect that Elanco Animal Health will post 0.91 earnings per share for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Several hedge funds have recently bought and sold shares of ELAN. CoreCap Advisors LLC acquired a new stake in Elanco Animal Health in the fourth quarter valued at $29,000. AM Squared Ltd acquired a new position in shares of Elanco Animal Health during the 3rd quarter worth $34,000. Wilmington Savings Fund Society FSB purchased a new stake in shares of Elanco Animal Health in the 3rd quarter worth about $35,000. Farther Finance Advisors LLC grew its stake in Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock valued at $49,000 after acquiring an additional 2,044 shares during the last quarter. Finally, Venturi Wealth Management LLC increased its holdings in Elanco Animal Health by 89.9% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after acquiring an additional 1,601 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.